US start-up Allermi said that it has raised $3.5 million in a seed round led by Nelstone Ventures for “the world’s first custom approach offered by Allermi that combines and adjusts the doses of multiple clinically-proven medications into one nasal spray bottle to address patients’ specific symptoms.” The company says that its nasal spray service is currently available in 28 US states, and the new funding will go toward continued expansion.
According to the Allermi web site, the cost of a personalized compounded formulation containing varying amounts of ipratropium, azelastine, oxymetazoline, and triamcinolone — with up to all 4 APIs in combination — includes an online consultation with an allergist. The site says that its nasal sprays are “full prescription strength,” “fast-acting within 10 minutes,” and provide “complete relief” for up to 24 hours.
Nelstone Ventures Managing Director Rich Nelson said, “We first met the Allermi team nearly a year ago and were intrigued by their approach to improving patient care for rhinitis and allergy sufferers through their customized solutions and telemedicine offering. Since then, we have been very impressed with all that CEO Shani Bocian and the rest of the team have accomplished and are very excited to partner with them as they enter their next phase of growth and expansion.”
Bocian commented, “There are approximately 110 million Americans that suffer from nasal congestion and rhinitis. With a custom combination of the right medications at the right dosage, millions of rhinitis sufferers can now achieve far superior relief compared to one-size-fits-all options at the drugstore. This recent funding will allow us to continue innovating our customized solution and make it accessible to allergy sufferers nationwide.”
Read the Allermi press release.
